Madrigal Pharmaceuticals(US:MDGL)2026-02-19 14:09Financial Performance - The company has an accumulated deficit of $2,090.5 million as of December 31, 2025, and has incurred losses since inception [422]. - Product revenue for the year ended December 31, 2025, was $958.4 million, a 432% increase from $180.1 million in 2024, driven by increased demand for Rezdiffra and a full year of commercialization [448]. - Cost of sales for 2025 was $56.1 million, up 801% from $6.2 million in 2024, reflecting the same factors as product revenue [449]. - Research and development expenses increased to $388.5 million in 2025, a 64% rise from $236.7 million in 2024, primarily due to business development transactions [450]. - Selling, general and administrative expenses rose to $813.8 million in 2025, an 87% increase from $435.1 million in 2024, mainly due to increased commercial activities for Rezdiffra [451]. - Interest income decreased to $37.4 million in 2025 from $46.7 million in 2024, primarily due to higher principal balances and interest rates [452]. - Interest expense increased to $22.3 million in 2025, up 52% from $14.7 million in 2024, due to a higher average outstanding principal balance [453]. - For the year ended December 31, 2025, net cash used in operating activities was $189.6 million, primarily due to losses from operations [475]. - The company reported net cash provided by financing activities of $735.1 million for the year ended December 31, 2024, mainly from the 2024 Offering [480]. Product Development and Commercialization - Rezdiffra, the company's medication for MASH, was approved by the FDA in March 2024 and began generating revenue in April 2024 [419]. - The company launched Rezdiffra in Germany in September 2025, marking it as the first medication approved for noncirrhotic MASH with moderate to advanced liver fibrosis [419]. - The company plans to evaluate additional therapies to expand the eligible patient population for Rezdiffra [423]. - The company expects fluctuations in financial results based on net sales of Rezdiffra and the progress of research and development efforts [423]. - The company has acquired rights to several new drug candidates, including MGL-2086 and ervogastat, to enhance its pipeline for MASH treatment [420]. - The company received FDA approval for Rezdiffra in March 2024 and EC approval in August 2025, with a tiered royalty payable to Roche on net sales [484]. - In July 2025, the company entered into a license agreement with CSPC for MGL-2086, paying an upfront fee of $120.0 million and potential milestone payments of up to $2.0 billion [485]. Operational Expenses and Future Outlook - The company expects to incur additional operating losses due to planned expenditures for commercializing Rezdiffra and expanding operations in Europe [422]. - Research and development expenses are expected to remain substantial as the company conducts clinical trials and manufacturing studies [429]. - Selling, general and administrative expenses are anticipated to increase as the company expands its operations and commercialization efforts [433]. - The company anticipates continued losses until sufficient revenue is generated from Rezdiffra and other future products, with potential future capital needs for operations [457]. Financing and Cash Position - As of December 31, 2025, cash, cash equivalents, restricted cash, and marketable securities totaled $988.6 million, compared to $931.3 million in 2024 [455]. - The company entered into a Financing Agreement on July 17, 2025, providing up to $500.0 million in senior secured credit facilities [462]. - As of December 31, 2025, the outstanding principal under the Financing Agreement was $350.0 million, with an interest rate of 8.75% [467]. - The company has approximately $268.3 million in obligations related to agreements for active pharmaceutical ingredients as of December 31, 2025 [488]. - The company has not entered into any hedging arrangements for foreign currency risk as it expands operations into Europe [492]. - Inflation has not materially affected the company's financial condition or results of operations during the years ended December 31, 2025, 2024, or 2023 [494]. Public Offerings - In March 2024, the company completed a public offering, selling 750,000 shares at $260.00 per share and pre-funded warrants for 1,557,692 shares at $259.9999 each, raising approximately $659.9 million in net proceeds [468][469]. - The 2023 public offering closed on October 3, 2023, with gross proceeds of $500.0 million and net proceeds of approximately $472.0 million after expenses [471][472].